Expertise in
25
conditions

Georges Deschenes

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
25
conditions
Paris, FR 

Overview

Georges Deschenes practices practicing medicine in Paris, France.

Mr. Deschenes is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Cystinosis, Kidney Transplant, and Liver Transplant.

He is actively involved in clinical research, co-authoring 136 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Paris, France
Other Locations
Caen, 14033, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients
A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients
Enrollment Status: Recruiting
Publish Date: February 27, 2026
Intervention Type: Biological
Study Drug: PED-HZ/su
Study Phase: Phase 1/Phase 2
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Biological
Study Drug: TAK-755
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: BAX930
Study Phase: Phase 3
A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Enrollment Status: Completed
Publish Date: December 10, 2021
Intervention Type: Other, Biological
Study Drug: Oxabact OC5 - Oxalobacter formigenes HC-1
Study Phase: Phase 3
Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria
Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria
Enrollment Status: Completed
Publish Date: March 26, 2021
Intervention Type: Drug
Study Phase: Phase 2
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Enrollment Status: Completed
Publish Date: July 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

136 Total Publications

Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: April 18, 2023

Frequently Asked Questions about Georges Deschenes

Is Georges Deschenes a top-rated expert for Primary Hyperoxaluria?

MediFind is an objective health platform that identifies experts based on real-world data. Georges Deschenes is classified as an Elite expert for Primary Hyperoxaluria, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Georges Deschenes participate in research or clinical trials?

Yes. Georges Deschenes has published 136 articles and abstracts on conditions like Primary Hyperoxaluria. You can view a list of Georges Deschenes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Deschenes's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile